ABSTRACT
This is the first report of the health economic benefits derived from preventing infections through Immunoglobulin Replacement Therapy (IgRT) in patients with secondary immunodeficiency due to hematological malignancies. We conducted a retrospective population-based cohort study using patient medical history and pharmacy data from the Hospital Clínico San Carlos for 21 patients between 2011 and 2020. The pharmacoeconomic impact of using prophylactic IgRT was assessed by comparing characteristics of the SID patients 1 year before and after initiating IgRT measured by direct medical and tangible indirect costs. Results indicate a marked reduction in hospitalization days following IgRT initiation, decreasing from an average of 13.9 to 6.1 days per patient, with the elimination of ICU admissions. While emergency department visits decreased significantly, the number of routine consultations remained unchanged. Notably, absenteeism from work dropped substantially. The financial analysis revealed significant reductions in medication use and fewer ancillary tests, resulting in considerable cost savings. Specifically, total expenditure dropped from 405,088.18 pre-IgRT to 295,804.42 post-IgRT-including the cost of IgRT itself at 156,309.60. Overall, the annual savings amounted to 109,283.84, validating the cost-effectiveness of IgRT in managing SID in patients with hematological cancers.
Subject(s)
Cost-Benefit Analysis , Hematologic Neoplasms , Humans , Hematologic Neoplasms/therapy , Hematologic Neoplasms/economics , Male , Female , Retrospective Studies , Middle Aged , Adult , Immunologic Deficiency Syndromes/economics , Immunologic Deficiency Syndromes/therapy , Immunologic Deficiency Syndromes/drug therapy , Immunization, Passive/economics , Aged , Health Care Costs , Hospitalization/economicsABSTRACT
It has been proposed that the onset of Acquired Thrombotic Thrombocytopenic Purpura (iTTP) is more severe than subsequent relapses; however, existing studies have limitations. We conducted a retrospective observational study to compare analytical and clinical severity of onset and relapse aTTP cases between 2012 and 2023. A total of 370 episodes of aTTP were analyzed, comprising 272 at initial diagnosis and 98 relapses. At onset, analytical parameters indicative of severity (low hemoglobin, low platelet count, and increased LDH) were significantly worse; patients had severe neurological symptoms (p<0.001) and ≥ 3 points in the TMA mortality score (p<0.001). In conclusion, the onset of aTTP is associated with worse analytical parameters and severe neurological involvement.
Subject(s)
Purpura, Thrombotic Thrombocytopenic , Humans , Purpura, Thrombotic Thrombocytopenic/diagnosis , Purpura, Thrombotic Thrombocytopenic/therapy , Retrospective Studies , Recurrence , ADAMTS13 ProteinABSTRACT
La macroglobulinemia de Waldenström es un linfoma linfoplasmocítico caracterizado por una proliferación monoclonal de linfocitos B productores de inmunoglobulina M que infiltran la médula ósea. Las manifestaciones neurológicas asociadas a la macroglobulinemia de Waldenström suelen ser debidas al fenómeno de hiperviscosidad o a neuropatías desmielinizantes mediadas por inmunoglobulina M. Cuando la afectación neurológica es debida a la infiltración del sistema nervioso central por las células linfoplasmocitoides, se produce un síndrome denominado de Bing-Neel, con baja prevalencia y variedad de manifestaciones clínicas. Se presenta el caso clínico de una mujer de 76 años con antecedentes de macroglobulinemia de Waldenström, con un cuadro neurológico repentino de alteración del lenguaje y torpeza en la mano derecha. Cabe destacar la relevancia del laboratorio clínico en el diagnóstico del síndrome de Bing-Neel y en el seguimiento del tratamiento (AU)
Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma defined by a monoclonal proliferation of bone marrow infiltrating immunoglobulin M producing B lymphocytes. Neurological simptoms of Waldenström macroglobulinemia are mainly dominated by signs of hyperviscosity and autoimmune neuropathies mediated by immunoglobulin M. Neurological involvement secondary to the infiltration of IgM producing B lymphocytes, is defined as a Bing-Neel syndrome. This syndrome has a low prevalence and the clinical manifestations are variable. The case described is about a 76 year-old female with a history of Waldenström macroglobulinemia, who presents sudden neurological signs such as alteration of spoken language and clumsiness of the right hand. The clinical laboratory has a primary role in the diagnosis of Bing-Neel syndrome and monitoring of the treatment (AU)